Metastatic Breast Cancer – Pipeline Review, H2 2016

List of Tables

Number of Products under Development for Metastatic Breast Cancer, H2 2016 38

Number of Products under Development for Metastatic Breast Cancer – Comparative Analysis, H2 2016 39

Number of Products under Development by Companies, H2 2016 40

Number of Products under Development by Companies, H2 2016 (Contd..1) 41

Number of Products under Development by Companies, H2 2016 (Contd..2) 42

Number of Products under Development by Companies, H2 2016 (Contd..3) 43

Number of Products under Development by Companies, H2 2016 (Contd..4) 44

Number of Products under Development by Companies, H2 2016 (Contd..5) 45

Number of Products under Development by Companies, H2 2016 (Contd..6) 46

Number of Products under Development by Companies, H2 2016 (Contd..7) 47

Number of Products under Development by Companies, H2 2016 (Contd..8) 48

Number of Products under Development by Companies, H2 2016 (Contd..9) 49

Number of Products under Investigation by Universities/Institutes, H2 2016 50

Comparative Analysis by Late Stage Development, H2 2016 51

Comparative Analysis by Clinical Stage Development, H2 2016 52

Comparative Analysis by Early Stage Development, H2 2016 53

Comparative Analysis by Unknown Stage Development, H2 2016 54

Products under Development by Companies, H2 2016 55

Products under Development by Companies, H2 2016 (Contd..1) 56

Products under Development by Companies, H2 2016 (Contd..2) 57

Products under Development by Companies, H2 2016 (Contd..3) 58

Products under Development by Companies, H2 2016 (Contd..4) 59

Products under Development by Companies, H2 2016 (Contd..5) 60

Products under Development by Companies, H2 2016 (Contd..6) 61

Products under Development by Companies, H2 2016 (Contd..7) 62

Products under Development by Companies, H2 2016 (Contd..8) 63

Products under Development by Companies, H2 2016 (Contd..9) 64

Products under Development by Companies, H2 2016 (Contd..10) 65

Products under Development by Companies, H2 2016 (Contd..11) 66

Products under Development by Companies, H2 2016 (Contd..12) 67

Products under Development by Companies, H2 2016 (Contd..13) 68

Products under Development by Companies, H2 2016 (Contd..14) 69

Products under Development by Companies, H2 2016 (Contd..15) 70

Products under Development by Companies, H2 2016 (Contd..16) 71

Products under Investigation by Universities/Institutes, H2 2016 72

Metastatic Breast Cancer – Pipeline by 3SBio Inc, H2 2016 73

Metastatic Breast Cancer – Pipeline by AB Science SA, H2 2016 74

Metastatic Breast Cancer – Pipeline by AbbVie Inc, H2 2016 75

Metastatic Breast Cancer – Pipeline by Acceleron Pharma Inc, H2 2016 76

Metastatic Breast Cancer – Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 77

Metastatic Breast Cancer – Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 78

Metastatic Breast Cancer – Pipeline by Advaxis Inc, H2 2016 79

Metastatic Breast Cancer – Pipeline by Advenchen Laboratories LLC, H2 2016 80

Metastatic Breast Cancer – Pipeline by Alteogen Inc, H2 2016 81

Metastatic Breast Cancer – Pipeline by Amarna Therapeutics BV, H2 2016 82

Metastatic Breast Cancer – Pipeline by Ambrx Inc, H2 2016 83

Metastatic Breast Cancer – Pipeline by Amgen Inc, H2 2016 84

Metastatic Breast Cancer – Pipeline by Aphios Corp, H2 2016 85

Metastatic Breast Cancer – Pipeline by Arvinas Inc, H2 2016 86

Metastatic Breast Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 87

Metastatic Breast Cancer – Pipeline by Astellas Pharma Inc, H2 2016 88

Metastatic Breast Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2016 89

Metastatic Breast Cancer – Pipeline by AstraZeneca Plc, H2 2016 90

Metastatic Breast Cancer – Pipeline by Bayer AG, H2 2016 91

Metastatic Breast Cancer – Pipeline by Beta Pharma Inc, H2 2016 92

Metastatic Breast Cancer – Pipeline by Biocon Ltd, H2 2016 93

Metastatic Breast Cancer – Pipeline by Bionovis SA, H2 2016 94

Metastatic Breast Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 95

Metastatic Breast Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 96

Metastatic Breast Cancer – Pipeline by Cantex Pharmaceuticals Inc, H2 2016 97

Metastatic Breast Cancer – Pipeline by Cascadian Therapeutics Inc, H2 2016 98

Metastatic Breast Cancer – Pipeline by CASI Pharmaceuticals Inc, H2 2016 99

Metastatic Breast Cancer – Pipeline by Celgene Corp, H2 2016 100

Metastatic Breast Cancer – Pipeline by Celldex Therapeutics Inc, H2 2016 101

Metastatic Breast Cancer – Pipeline by Cellectar Biosciences Inc, H2 2016 102

Metastatic Breast Cancer – Pipeline by Celltrion Inc, H2 2016 103

Metastatic Breast Cancer – Pipeline by Clovis Oncology Inc, H2 2016 104

Metastatic Breast Cancer – Pipeline by Corcept Therapeutics Inc, H2 2016 105

Metastatic Breast Cancer – Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 106

Metastatic Breast Cancer – Pipeline by Curadis GmbH, H2 2016 107

Metastatic Breast Cancer – Pipeline by Curaxys SL, H2 2016 108

Metastatic Breast Cancer – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 109

Metastatic Breast Cancer – Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 110

Metastatic Breast Cancer – Pipeline by DexTech Medical AB, H2 2016 111

Metastatic Breast Cancer – Pipeline by Dompe Farmaceutici SpA, H2 2016 112

Metastatic Breast Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 113

Metastatic Breast Cancer – Pipeline by EirGenix Inc, H2 2016 114

Metastatic Breast Cancer – Pipeline by Eisai Co Ltd, H2 2016 115

Metastatic Breast Cancer – Pipeline by Eli Lilly and Company, H2 2016 116

Metastatic Breast Cancer – Pipeline by Ensol Biosciences Inc, H2 2016 117

Metastatic Breast Cancer – Pipeline by EOS Biosciences Inc, H2 2016 118

Metastatic Breast Cancer – Pipeline by Epigen Biosciences Inc, H2 2016 119

Metastatic Breast Cancer – Pipeline by Etubics Corp, H2 2016 120

Metastatic Breast Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 121

Metastatic Breast Cancer – Pipeline by FibroGen Inc, H2 2016 122

Metastatic Breast Cancer – Pipeline by Gene Techno Science Co Ltd, H2 2016 123

Metastatic Breast Cancer – Pipeline by Genelux Corp, H2 2016 124

Metastatic Breast Cancer – Pipeline by Genentech Inc, H2 2016 125

Metastatic Breast Cancer – Pipeline by Genor BioPharma Co Ltd, H2 2016 126

Metastatic Breast Cancer – Pipeline by Gilead Sciences Inc, H2 2016 127

Metastatic Breast Cancer – Pipeline by Glycotope GmbH, H2 2016 128

Metastatic Breast Cancer – Pipeline by GP Pharm SA, H2 2016 129

Metastatic Breast Cancer – Pipeline by GTx Inc, H2 2016 130

Metastatic Breast Cancer – Pipeline by Halozyme Therapeutics Inc, H2 2016 131

Metastatic Breast Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 132

Metastatic Breast Cancer – Pipeline by Hetero Drugs Ltd, H2 2016 133

Metastatic Breast Cancer – Pipeline by Humorigin Biotechnology Corp, H2 2016 134

Metastatic Breast Cancer – Pipeline by Immune Design Corp, H2 2016 135

Metastatic Breast Cancer – Pipeline by Immunomedics Inc, H2 2016 136

Metastatic Breast Cancer – Pipeline by Immunophotonics Inc, H2 2016 137

Metastatic Breast Cancer – Pipeline by Immupharma Plc, H2 2016 138

Metastatic Breast Cancer – Pipeline by Incyte Corp, H2 2016 139

Metastatic Breast Cancer – Pipeline by Intas Pharmaceuticals Ltd, H2 2016 140

Metastatic Breast Cancer – Pipeline by Ionis Pharmaceuticals Inc, H2 2016 141

Metastatic Breast Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 142

Metastatic Breast Cancer – Pipeline by Johnson & Johnson, H2 2016 143

Metastatic Breast Cancer – Pipeline by Kadmon Corp LLC, H2 2016 144

Metastatic Breast Cancer – Pipeline by Kancera AB, H2 2016 145

Metastatic Breast Cancer – Pipeline by Karyopharm Therapeutics Inc, H2 2016 146

Metastatic Breast Cancer – Pipeline by Laboratoires Pierre Fabre SA, H2 2016 147

Metastatic Breast Cancer – Pipeline by Mabion SA, H2 2016 148

Metastatic Breast Cancer – Pipeline by MacroGenics Inc, H2 2016 149

Metastatic Breast Cancer – Pipeline by MandalMed Inc, H2 2016 150

Metastatic Breast Cancer – Pipeline by Meabco A/S, H2 2016 151

Metastatic Breast Cancer – Pipeline by MedImmune LLC, H2 2016 152

Metastatic Breast Cancer – Pipeline by Medivation Inc, H2 2016 153

Metastatic Breast Cancer – Pipeline by Merck & Co Inc, H2 2016 154

Metastatic Breast Cancer – Pipeline by Merck KGaA, H2 2016 155

Metastatic Breast Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 156

Metastatic Breast Cancer – Pipeline by Merus NV, H2 2016 157

Metastatic Breast Cancer – Pipeline by MetaStat Inc, H2 2016 158

Metastatic Breast Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 159

Metastatic Breast Cancer – Pipeline by Morphotek Inc, H2 2016 160

Metastatic Breast Cancer – Pipeline by Mycenax Biotech Inc, H2 2016 161

Metastatic Breast Cancer – Pipeline by NantKwest Inc, H2 2016 162

Metastatic Breast Cancer – Pipeline by Natco Pharma Ltd, H2 2016 163

Metastatic Breast Cancer – Pipeline by Nektar Therapeutics, H2 2016 164

Metastatic Breast Cancer – Pipeline by Neonc Technologies Inc, H2 2016 165

Metastatic Breast Cancer – Pipeline by NewLink Genetics Corp, H2 2016 166

Metastatic Breast Cancer – Pipeline by Nippon Kayaku Co Ltd, H2 2016 167

Metastatic Breast Cancer – Pipeline by Northwest Biotherapeutics Inc, H2 2016 168

Metastatic Breast Cancer – Pipeline by Novartis AG, H2 2016 169

Metastatic Breast Cancer – Pipeline by Oasmia Pharmaceutical AB, H2 2016 170

Metastatic Breast Cancer – Pipeline by OBI Pharma Inc, H2 2016 171

Metastatic Breast Cancer – Pipeline by Oncobiologics Inc, H2 2016 172

Metastatic Breast Cancer – Pipeline by Oncolytics Biotech Inc, H2 2016 173

Metastatic Breast Cancer – Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 174

Metastatic Breast Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 175

Metastatic Breast Cancer – Pipeline by Panacea Pharmaceuticals Inc, H2 2016 176

Metastatic Breast Cancer – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 177

Metastatic Breast Cancer – Pipeline by Pfizer Inc, H2 2016 178

Metastatic Breast Cancer – Pipeline by Pharma Mar SA, H2 2016 179

Metastatic Breast Cancer – Pipeline by PIQUR Therapeutics AG, H2 2016 180

Metastatic Breast Cancer – Pipeline by Plexxikon Inc, H2 2016 181

Metastatic Breast Cancer – Pipeline by Polaris Pharmaceuticals Inc, H2 2016 182

Metastatic Breast Cancer – Pipeline by Polyphor Ltd, H2 2016 183

Metastatic Breast Cancer – Pipeline by Prescient Therapeutics Ltd, H2 2016 184

Metastatic Breast Cancer – Pipeline by Prima BioMed Ltd, H2 2016 185

Metastatic Breast Cancer – Pipeline by Puma Biotechnology Inc, H2 2016 186

Metastatic Breast Cancer – Pipeline by Radius Health Inc, H2 2016 187

Metastatic Breast Cancer – Pipeline by Richter Gedeon Nyrt, H2 2016 188

Metastatic Breast Cancer – Pipeline by Samyang Holdings Corp, H2 2016 189

Metastatic Breast Cancer – Pipeline by Sanofi, H2 2016 190

Metastatic Breast Cancer – Pipeline by Seattle Genetics Inc, H2 2016 191

Metastatic Breast Cancer – Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016 192

Metastatic Breast Cancer – Pipeline by Sorrento Therapeutics Inc, H2 2016 193

Metastatic Breast Cancer – Pipeline by Starpharma Holdings Ltd, H2 2016 194

Metastatic Breast Cancer – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 195

Metastatic Breast Cancer – Pipeline by SynCore Biotechnology Co Ltd, H2 2016 196

Metastatic Breast Cancer – Pipeline by Syndax Pharmaceuticals Inc, H2 2016 197

Metastatic Breast Cancer – Pipeline by Synthon Holdings BV, H2 2016 198

Metastatic Breast Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 199

Metastatic Breast Cancer – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 200

Metastatic Breast Cancer – Pipeline by Tocagen Inc, H2 2016 201

Metastatic Breast Cancer – Pipeline by Transgene Biotek Ltd, H2 2016 202

Metastatic Breast Cancer – Pipeline by Tyme Technologies Inc, H2 2016 203

Metastatic Breast Cancer – Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016 204

Metastatic Breast Cancer – Pipeline by Vertex Pharmaceuticals Inc, H2 2016 205

Metastatic Breast Cancer – Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 206

Metastatic Breast Cancer – Pipeline by Vyriad Inc, H2 2016 207

Metastatic Breast Cancer – Pipeline by Wilex AG, H2 2016 208

Metastatic Breast Cancer – Pipeline by WntResearch AB, H2 2016 209

Metastatic Breast Cancer – Pipeline by ZIOPHARM Oncology Inc, H2 2016 210

Metastatic Breast Cancer – Pipeline by Zymeworks Inc, H2 2016 211

Assessment by Monotherapy Products, H2 2016 212

Assessment by Combination Products, H2 2016 213

Number of Products by Stage and Target, H2 2016 215

Number of Products by Stage and Mechanism of Action, H2 2016 229

Number of Products by Stage and Route of Administration, H2 2016 244

Number of Products by Stage and Molecule Type, H2 2016 246

Metastatic Breast Cancer – Dormant Projects, H2 2016 1060

Metastatic Breast Cancer – Dormant Projects (Contd..1), H2 2016 1061

Metastatic Breast Cancer – Dormant Projects (Contd..2), H2 2016 1062

Metastatic Breast Cancer – Dormant Projects (Contd..3), H2 2016 1063

Metastatic Breast Cancer – Dormant Projects (Contd..4), H2 2016 1064

Metastatic Breast Cancer – Dormant Projects (Contd..5), H2 2016 1065

Metastatic Breast Cancer – Dormant Projects (Contd..6), H2 2016 1066

Metastatic Breast Cancer – Dormant Projects (Contd..7), H2 2016 1067

Metastatic Breast Cancer – Dormant Projects (Contd..8), H2 2016 1068

Metastatic Breast Cancer – Dormant Projects (Contd..9), H2 2016 1069

Metastatic Breast Cancer – Dormant Projects (Contd..10), H2 2016 1070

Metastatic Breast Cancer – Dormant Projects (Contd..11), H2 2016 1071

Metastatic Breast Cancer – Dormant Projects (Contd..12), H2 2016 1072

Metastatic Breast Cancer – Dormant Projects (Contd..13), H2 2016 1073

Metastatic Breast Cancer – Dormant Projects (Contd..14), H2 2016 1074

Metastatic Breast Cancer – Dormant Projects (Contd..15), H2 2016 1075

Metastatic Breast Cancer – Discontinued Products, H2 2016 1076

Metastatic Breast Cancer – Discontinued Products (Contd..1), H2 2016 1077

Metastatic Breast Cancer – Discontinued Products (Contd..2), H2 2016 1078

Metastatic Breast Cancer – Discontinued Products (Contd..3), H2 2016 1079

Metastatic Breast Cancer – Discontinued Products (Contd..4), H2 2016 1080

Metastatic Breast Cancer – Discontinued Products (Contd..5), H2 2016 1081